Forum Topic News
  • Conversation: Encouraging data for ViiV’s long-acting, two-drug HIV therapy

    • October 30, 2018 5:24 PM GMT
    • Encouraging data for ViiV’s long-acting, two-drug HIV therapy

      ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
      According to long-term data from the Phase II LATTE-2 trial, the injectable regimen - administered either every eight weeks or every four weeks - showed “high rates of virologic response, long-term durability of virologic response and good overall tolerability,” the firm noted.
      At 160 weeks, 90% and 83% of the patients receiving the injectable cabotegravir/rilpivirine every eight and four weeks, respectively, remained virally suppressed.
      Read more: http://www.pharmatimes.com/news/encouraging_data_for_viivs_long-acting,_two-drug_hiv_therapy_1257551

Add Reputation

Do you want to add reputation for this member by this post?

or cancel